Business Context and Reporting Period
This Form 8-K is a current report filed by Cara Therapeutics, Inc. (not Tvardi Therapeutics, Inc.) on August 2, 2023. The filing discloses corporate governance changes, specifically the appointment of a new director to the Board of Directors.
Key Financial Metrics
The filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The only financial figures disclosed relate to director compensation:
- Initial Stock Option Grant: Black-Scholes value of $350,000, vesting over three years in quarterly installments.
- Annual Cash Retainer (Director): $50,000.
- Annual Cash Retainer (Audit Committee): $10,000.
Material Changes
The primary material change reported is the appointment of Helen M. Boudreau, M.B.A. to the Board of Directors, effective August 2, 2023. Her term expires at the 2024 Annual Meeting of Stockholders. She has been appointed to serve on the Audit Committee. No other material changes to operations or financial status are reported in this document.
Guidance, Outlook, and Risks
This filing does not provide financial guidance, operational outlook, or discuss specific business risks. The Board cited Ms. Boudreau's financial expertise and extensive experience with biopharmaceutical companies as the rationale for her appointment. The filing notes that the press release accompanying this report is not deemed "filed" for purposes of Section 18 of the Exchange Act.
Investor Verification Checklist
- Verify the correct registrant name is Cara Therapeutics, Inc. (Ticker: CARA), as the input metadata incorrectly referenced "Tvardi Therapeutics."
- Confirm the effective date of the new director's appointment is August 2, 2023.
- Review the full press release (Exhibit 99.1) for additional context on the Board's strategic direction.
- Note that this filing contains no financial results; refer to the most recent 10-Q or 10-K for financial metrics.